One more British vaccine reached the second phase of the human trial

London, Ta. Saturday 18 July 2020

The Corona virus vaccine from Imperial College London has reached the second phase of the human trial. Scientists affiliated with it claim that the vaccine has shown a good effect during the first phase.

During the trial, 105 people between the ages of 18 and 75 will be vaccinated in the second phase. After four weeks all participants will be given a booster dose. The Imperial College team is keeping a close eye on the health of all participants involved in the clinical trial.

So far no adverse effects have been reported on the vaccine. The team will also examine the blood of all participants to collect data linked to this vaccine. The third trial of the vaccine will be held in November after the second phase of the human trial, scientists involved in the project said.

Meanwhile, the vaccine is planned to be tested on 6,000 people. The Imperial College team has expressed the possibility that the vaccine could go into production in early 2021.

Significantly, there are currently more than 130 participants working on the corona virus vaccine in the world. While 13 of these vaccines have reached the phase of clinical trials. Most of these vaccines are in human trials in China. Importantly, 5 vaccines in China, 2 in Britain, 3 in the United States, 1-1 vaccines in Russia, Australia and Germany are in the clinical trial phase.